Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN EBITDA Margin

EBITDA as a percentage of revenue.

Guardian Pharmacy Services, Inc.NYSE: GRDN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 10.2%

EBITDA Margin was 10.2% in Q2 FY2026, up 4.9 pp from a year earlier. On a trailing-twelve-month basis it was 8.2%, up 11.3 pp year over year. Over 3 fiscal years it narrowed by 0.8 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 10.0% for the fiscal year ending Dec 2026, up from 6.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
10.2%+2.9 pp QoQ
Last fiscal yearDec 2025
6.7%+10.2 pp YoY
LTMJun 2026
8.2%+11.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+4.9 pp+3.3 pp-1.5 pp
1 year+10.2 pp+3.3 pp-6.9 pp
3 years-0.8 pp+3.6 pp+4.5 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
6.7%
Year-over-year change
+10.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 EBITDA Margin of 8.2% is the 3rd highest of the 10 companies compared; the peer median is -28.3%.
  • Its year-over-year change of +11.3 pp is the 4th highest of 10, against a peer median of +3.8 pp.
  • Over three fiscal years its change of -0.8 pp compares with a peer median of +16.6 pp.
GRDN Competitors Peer median
EBITDA Margin for GRDN and competitors
Company Period LTM level YoY 3-year change
NHCNational HealthCare CorporationLTM Sep 202613.1% +0.5 pp+7.7 pp
MDPediatrix Medical Group, Inc.LTM Sep 202612.8% -0.7 pp+6.4 pp
GRDNGuardian Pharmacy Services, Inc.LTM Jun 20268.2% +11.3 pp-0.8 pp
TXG10x Genomics, Inc.LTM Sep 20266.1% +10.9 pp+25.5 pp
QDELQuidelOrtho CorporationLTM Mar 2026-20.7% -31.1 pp-51.4 pp
TWSTTwist Bioscience CorporationLTM Sep 2026-28.3% -14.5 pp+42.8 pp
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026-28.6% +3.8 pp+77.8 pp
MESOMesoblast LimitedLTM Jun 2026-37.4% +300.9 pp+745.1 pp
NUVBNuvation Bio Inc.LTM Jun 2026-74.8% +1326.6 pp—
JANXJanux Therapeutics, Inc.LTM Mar 2026-520.3% +290.5 pp-393.5 pp
EWTXEdgewise Therapeutics, Inc.FY2025— ——
Peer median (excluding GRDN) -28.3%+3.8 pp+16.6 pp

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue792.07M908.91M1.05B1.23B1.45B
Cost of Revenue630.81M723.04M837.88M984.04M1.17B
Gross Profit161.27M185.87M208.31M244.37M282.04M
Gross Margin20.4%20.4%19.9%19.9%19.5%
Research & Development00000
Selling, General & Admin131.12M133.88M167.36M307.29M193.13M
Operating Expenses131.12M133.88M167.36M307.29M193.13M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
EBITDA46.49M68.15M58.81M(43.43M)96.42M
EBITDA Margin5.9%7.5%5.6%-3.5%6.7%
Operating Income30.15M51.99M40.95M(62.92M)88.91M
Operating Margin3.8%5.7%3.9%-5.1%6.1%
Interest Income00000
Interest Expense1.64M1.93M2.86M3.28M665K
Other Income / Expenses(1.82M)(2.33M)(3.23M)(3.56M)(15.49M)
Income Before Tax28.33M49.66M37.72M(66.48M)73.42M
Pre-Tax Margin3.6%5.5%3.6%-5.4%5.1%
Income Tax Expense0004.56M24.47M
Net Income16.31M35.42M23.9M(87.29M)49.22M
Net Margin2.1%3.9%2.3%-7.1%3.4%
EPS (Basic)0.270.580.39(1.77)0.79
EPS (Diluted)0.270.580.39(1.77)0.78
Weighted Avg Shares60.84M60.84M60.84M62.01M62.39M
Weighted Avg Shares (Diluted)60.84M60.84M60.84M62.01M63.3M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.